NateraNTRA
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 3,293
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
75% more call options, than puts
Call options by funds: $43.1M | Put options by funds: $24.7M
20% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 54
14% more capital invested
Capital invested by funds: $13.4B [Q2] → $15.3B (+$1.85B) [Q3]
2% more funds holding
Funds holding: 472 [Q2] → 483 (+11) [Q3]
9% less repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 192
3.71% less ownership
Funds ownership: 100.89% [Q2] → 97.18% (-3.71%) [Q3]
4% less funds holding in top 10
Funds holding in top 10: 25 [Q2] → 24 (-1) [Q3]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
13 analyst ratings
Piper Sandler David Westenberg 45% 1-year accuracy 9 / 20 met price target | 23%upside $200 | Overweight Maintained | 18 Nov 2024 |
Morgan Stanley Tejas Savant 33% 1-year accuracy 3 / 9 met price target | 9%upside $176 | Overweight Maintained | 14 Nov 2024 |
TD Cowen Dan Brennan 31% 1-year accuracy 8 / 26 met price target | 8%upside $175 | Buy Maintained | 13 Nov 2024 |
Craig-Hallum Alexander Nowak 57% 1-year accuracy 8 / 14 met price target | 3%downside $157 | Buy Maintained | 13 Nov 2024 |
JP Morgan Julia Qin 25% 1-year accuracy 1 / 4 met price target | 1%downside $160 | Overweight Maintained | 13 Nov 2024 |
Financial journalist opinion
Based on 12 articles about NTRA published over the past 30 days
